drugset
drugset / Trial / NCT00501826

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT00501826 ↗

Phase 2 Recruiting 160 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab
NaSingle-groupTreatment

Summary

This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, mercaptopurine, prednisone, pegaspargase, nelarabine, and venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Timeline

Start
2007-07-11
Primary completion
2026-10-31
Completion
2026-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Nelarabine Small molecule — Intravenous
Subject Pegaspargase Protein / enzyme biologic — Intravenous
Subject Venetoclax Small molecule — Oral
Background Cyclophosphamide Other / unclassified — Intravenous
Background Cytarabine Small molecule — Intravenous
Background Dexamethasone Small molecule — Intravenous
Background Doxorubicin Other / unclassified — Intravenous
Background MERCAPTOPURINE ANHYDROUS Small molecule — Oral
Background Methotrexate Small molecule — Intravenous
Background Prednisone Other / unclassified — Oral
Background Vincristine Small molecule — Intravenous

Indications

T-cell acute lymphoblastic leukemia T-lymphoblastic lymphoma